Yang
88 IP cases indexed. Covers patent matters.
Cases Presided Over
88 cases indexed | Page 2 of 3
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over a combination of prior‑art references, rendering the patent entirely unpatentable.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over prior art references Gwozdz, Meezan ’962, and Cartt ’784, rendering the patent entirely unpatentable.
CSPC Pharmaceutical Group Limited et al. v.Ipsen Biopharm Ltd. et al.
The PTAB institution decision in this oncology IPR upheld the patent claims against numerous prior art references related to FOLFIRINOX and nanoliposomal irinotecan. The Board adopted a specific claim construction defining 'treatment' as requiring more than a de minimis therapeutic benefit for the patient.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
The PTAB denied NeoGenomics’s petition to institute an IPR against Natera’s 11,530,454 patent covering liquid‑biopsy methods. The Board found the prior art had already been considered and no material error existed. No trial will be held.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of Inari Agriculture's PGR against Pioneer Hi-Bred International regarding maize breeding claims. The Board found the Petitioner failed to demonstrate a reasonable expectation of success, specifically failing to adequately address the unique genotype (PH4CYJ) central to the patent.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of IPR against Ellodi Pharmaceuticals LP regarding patent 9,486,407. The Board found a reasonable likelihood that prior art (Dohil) renders Claim 35 obvious.
Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully petitioned to institute IPR against Ellodi Pharmaceuticals LP's patent (11,246,828) over orally disintegrating tablet claims. The Board found a reasonable likelihood of success based on prior art showing obviousness.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of Inter Partes Review against Ellodi Pharmaceuticals LP's patent (10632069). The review challenges claims 1-17 based on obviousness over prior art, including Dohil and FDA guidance.
QIAGEN Sciences, LLC v.Tecan Group AG
Tecan Group AG seeks Director Review to overturn the PTAB’s institution of QIAGEN’s IPR, arguing that parallel petitions create inefficiency and unfairness. The request cites statutory grounds under 35 U.S.C. § 316(b) and an Acting Director memo.
QIAGEN Sciences, LLC v.Tecan Group AG
Tecan Group AG seeks a Director Review to overturn the PTAB’s institution of QIAGEN’s IPR, arguing that parallel petitions create inefficiency and unfairness. The request relies on discretionary denial authority under 35 U.S.C. § 316(b).
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics, challenging claims of U.S. Patent No. 10876108 based on obviousness (35 U.S.C. § 103). The Board found that the Examiner erred in relying solely on secondary considerations, adopting the Petitioner's view that combining Shapero and Delseny renders multiple claims obvious.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned the PTAB against Tecan Genomics regarding claims related to Next-Generation Sequencing (NGS). The Board instituted review, finding a reasonable likelihood of prevailing on obviousness grounds.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics for patent number 11725241. The Board found sufficient evidence of unpatentability across multiple claims based on grounds of anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully convinced the PTAB to institute trial proceedings against Tecan Genomics, Inc. regarding a high-throughput sequencing patent (11098357). The Board found reasonable likelihood that claims 1 through 10 are unpatentable under both anticipation (§ 102) and obviousness (§ 103).
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies sought IPR of Tecan Genomics' patent covering nucleic acid technologies. The patent owner filed a terminal disclaimer of the entire patent, prompting the Board to grant an adverse judgment and terminate the proceeding.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB granted institution for an IPR challenging claims 1-16 of a nucleic acid analysis patent, finding reasonable likelihood of success. The Board rejected the Patent Owner's motion to deny based on prior art similarity, allowing the technical merits of anticipation and obviousness over Kivioja and Bielas to proceed to trial.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB instituted the IPR, finding a reasonable likelihood of unpatentability based on obviousness over Iafrate and Kivioja for key NGS claims. The Board also provided definitive claim constructions for 'indexing site' and 'identifier site.'
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies challenged Tecan Genomics's NGS patent (9546399) on grounds of anticipation and obviousness over prior art references Iafrate and Kivioja. The PTAB instituted the IPR, finding a reasonable likelihood that at least one claim is unpatentable under 35 U.S.C. § 103 over Iafrate and Kivioja.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina successfully petitioned the PTAB to institute trial against Molecular Loop Biosciences' patent claims related to genomic sequencing and analysis. The Board found a reasonable likelihood of prevailing on at least claim 1, allowing the IPR to proceed despite extensive prior art challenges under Sections 102 and 103.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB found multiple claims unpatentable under both § 102 (anticipation) and § 103 (obviousness). The decision centered on the combination of prior art references—specifically Iafrate, Kivioja, and Bielas—in the context of Next Generation Sequencing (NGS) technologies. Claim construction was finalized, defining key terms like 'identifier site' and 'indexing site'.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
The PTAB upheld the patentability of claims 1-9 for Molecular Loop Biosciences against Illumina. The Board rejected all grounds of anticipation and obviousness over prior art like Chee, finding that the required 'collapsing step' necessitates combining both target sequence and differentiator tag information.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
DR. FALK PHARMA GMBH v.Ellodi Pharmaceuticals LP
DR. FALK PHARMA GMBH challenged Ellodi Pharmaceuticals LP's '729 patent, asserting obviousness of claims related to orally disintegrating corticosteroids for GI tract inflammation. The PTAB declined to deny the petition, finding that additional evidence warranted reconsideration of prior art references like Dohil and FDA Guidance.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear entered a confidential settlement, prompting the PTAB to terminate the pending IPRs, including the case involving patent 10,869,510.
Nike, Inc. v.SherryWear, LLC et al.
Nike and SherryWear settled their IPR dispute over patent 9,808,036 B1. The Board granted a joint motion to terminate the proceedings, treating the settlement agreement as confidential.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear reached a confidential settlement, leading the PTAB to terminate a series of inter partes reviews, including the one covering patent 10,219,551. The termination was entered under 35 U.S.C. §317 after the trials had already been instituted.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear reached a confidential settlement, prompting the PTAB to terminate eight related IPRs without deciding the merits.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear reached a confidential settlement, leading the PTAB to terminate the IPRs covering patent 9,289,016. The Board granted the joint motion to terminate under 35 U.S.C. §317.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear jointly moved to terminate multiple IPRs after reaching a confidential settlement. The Board granted the termination and ordered the settlement agreement to remain confidential.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.